溴化3,4-(甲二氧基)苯基镁 | 17680-04-5

• 物质功能分类: 有机原料 - 有机金属类化合物 - 有机镁
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 溴化3,4-(甲二氧基)苯基镁
• 中文别名: 3,4-(METHYLENEDIOXY)PHENYLMAGNESIUMBROMIDESOLUTION1.0燤INTHF:TOLUENE(1:1)；3,4-(甲基二氧)苯基溴化镁；3,4-(亚甲基二氧基)苯基溴化镁；3,4-(METHYLENEDIOXY)PHENYLMAGNESIUM BROMIDE SOLUTION 1.0燤 IN THF: TOLUENE (1:1)
• 英文名称: 3,4-(Methylenedioxy)phenylmagnesiumbromide
• 英文别名: magnesium;5H-1,3-benzodioxol-5-ide;bromide
• CAS: 17680-04-5
• 化学式: C7H5BrMgO2
• 分子量: 225.32
• InChiKey: KLRLIDQAFFVFCV-UHFFFAOYSA-M

物化性质

• 密度：
  1.04 g/mL at 25 °C
• 闪点：
  14 °F
• 稳定性/保质期：
  按规定使用不会分解，应避免接触氧化剂、水分、高温、火焰和明火。

计算性质

• 辛醇/水分配系数(LogP)：
  -2.16
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  3
• 危险品标志：
  F,C
• 安全说明：
  S26
• 危险类别码：
  R11
• WGK Germany：
  2,3
• 海关编码：
  29329990
• 危险标志：
  GHS02,GHS05,GHS07,GHS08
• 危险品运输编号：
  UN 2924 3/PG 2
• 危险性描述：
  H225,H304,H314,H335,H336,H351,H361d,H373
• 危险性防范说明：
  P210,P260,P280,P305 + P351 + P338,P370 + P378,P403 + P235

反应信息

• 作为反应物：
  描述：

  溴化3,4-(甲二氧基)苯基镁 、 (5alpha,10alpha,17beta)-5,10-环氧-17-羟基-17-(1-丙炔-1-基)-雌甾-9(11)-烯-3-酮环1,2-乙二基缩醛 在 溴化3,4-(甲二氧基)苯基镁 作用下， 生成 (5'R,8'S,11'R,13'S,14'S,17'S)-11'-(1,3-benzodioxol-5-yl)-13'-methyl-17'-prop-1-ynylspiro[1,3-dioxolane-2,3'-2,4,6,7,8,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-5',17'-diol
  参考文献：
  名称：

  11-(substituted phenyl)-estra-4,9-diene derivatives

  摘要：

  本发明涉及一种公式I的11-(取代苯基)-雌-4,9-二烯衍生物，其中A、X、R1和R2如规范所定义。本发明的化合物具有抗糖皮质激素活性，可用于治疗或预防糖皮质激素依赖性疾病。

  公开号：

  US06011025A1
• 作为试剂：
  描述：

  溴化3,4-(甲二氧基)苯基镁 、 (5alpha,10alpha,17beta)-5,10-环氧-17-羟基-17-(1-丙炔-1-基)-雌甾-9(11)-烯-3-酮环1,2-乙二基缩醛 在 溴化3,4-(甲二氧基)苯基镁 作用下， 生成 (5'R,8'S,11'R,13'S,14'S,17'S)-11'-(1,3-benzodioxol-5-yl)-13'-methyl-17'-prop-1-ynylspiro[1,3-dioxolane-2,3'-2,4,6,7,8,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-5',17'-diol
  参考文献：
  名称：

  11-(substituted phenyl)-estra-4,9-diene derivatives

  摘要：

  本发明涉及一种公式I的11-(取代苯基)-雌-4,9-二烯衍生物，其中A、X、R1和R2如规范所定义。本发明的化合物具有抗糖皮质激素活性，可用于治疗或预防糖皮质激素依赖性疾病。

  公开号：

  US06011025A1

文献信息

• Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
  申请人：——

  公开号：US20040266793A1

  公开（公告）日：2004-12-30

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally; or a methylene group optionally substituted; R1 represents a pyrimidine group optionally substituted; R2 may represent a C 1-6 alkyl group optionally substituted by a C 6,10 aryloxy or a C 6,10 arylamino group; a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represents each independently a hydrogen atom, C 1-6 alkyl group, a hydroxy group, a C 1- 4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C 1-6 alkyl group or a halogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3&bgr;3 or GSK3&bgr;3 and cdk5/p25, such as Alzheimer disease. 1

  本发明涉及一种由式（I）表示的嘧啶酮衍生物或其盐，其中：X代表两个氢原子，硫原子，氧原子或C1-2烷基和氢原子；y代表键，乙烯基，乙炔基，氧原子，硫原子，磺酰基，亚磺酸基，羰基，氮原子（可选）或取代的亚甲基基团；R1表示可选取代的嘧啶基团；R2可以代表C1-6烷基，可选地被C6,10芳氧基或C6,10芳基氨基基团取代；C3-6环烷基，C1-4烷基硫基，C1-4烷氧基，C1-2全氟烷基，C1-3卤代烷基，苯硫基，苄基，苯环，茚环，5,6,7,8-四氢萘环，萘环，吡啶环，吡咯环，噻吩环，呋喃环或咪唑环；R3和R4各自独立地表示氢原子，C1-6烷基，羟基，C1-4烷氧基或卤素原子；R5表示氢原子，C1-6烷基或卤素原子。本发明还涉及一种药物，其中包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β3或GSK3β3和cdk5/p25的异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease
  申请人：——

  公开号：US20040127555A1

  公开（公告）日：2004-07-01

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&bgr; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双和三羟基芳基化合物及其亚甲二氧基类似物和药学上可接受的酯，其合成方法，包含它们的药物组成物，以及它们在治疗淀粉样疾病中的应用，特别是Aβ淀粉样蛋白病，如阿尔茨海默病，IAPP淀粉样蛋白病，如2型糖尿病中观察到的，以及突触核蛋白病，如帕金森病中观察到的，以及用于制造此类治疗药物。
• Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
  申请人：Snow D. Alan

  公开号：US20070225362A1

  公开（公告）日：2007-09-27

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双羟基和三羟基芳基化合物及其甲氧基二氧杂环化物和药学上可接受的酯类，它们的合成，含有它们的制药组合物，以及它们在治疗淀粉样疾病，特别是阿尔茨海默病中观察到的Aβ淀粉样变性，IAPP淀粉样变性，例如在2型糖尿病中观察到的AA / SAA淀粉样变性，以及突触蛋白病，例如在帕金森病中观察到的应用，以及用于制造这种治疗药物。
• Heterocyclic compounds and their uses as therapeutic agents
  申请人：Chafeev Mikhail

  公开号：US20060258659A1

  公开（公告）日：2006-11-16

  This invention is directed to heterocyclic compounds that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.

  本发明涉及杂环化合物，其可用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。还公开了包含该化合物的制药组合物和使用该化合物的方法。
• Spiro-oxindole compounds and their uses as therapeutic agents
  申请人：Chafeev Mikhail

  公开号：US20060252812A1

  公开（公告）日：2006-11-09

  This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R 1 , R 2a , R 2b , R 2c , R 2d , R 3a , R 3b , R 3c , and R 3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

  本发明涉及式（I）的螺环-氧吲哚化合物： 其中k，j，Q，R1，R2a，R2b，R2c，R2d，R3a，R3b，R3c和R3d如本说明书中所定义的那样，作为立体异构体，对映异构体，互变异构体或其混合物；或其药学上可接受的盐，溶剂化合物或前药，这些化合物对治疗和/或预防钠通道介导的疾病或病症，如疼痛，有用。还公开了包含这些化合物的制药组合物和制备和使用这些化合物的方法。